Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
AS Alzahrani - Seminars in cancer biology, 2019 - Elsevier
Abstract Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR)
signaling pathway is one of the major cellular signaling pathways that plays an important …
signaling pathway is one of the major cellular signaling pathways that plays an important …
Targeting Akt in cancer for precision therapy
H Hua, H Zhang, J Chen, J Wang, J Liu… - Journal of Hematology & …, 2021 - Springer
Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …
[HTML][HTML] PI3K/AKT/mTOR-targeted therapy for breast cancer
K Zhu, Y Wu, P He, Y Fan, X Zhong, H Zheng, T Luo - Cells, 2022 - mdpi.com
Phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of
rapamycin (mTOR)(PAM) pathways play important roles in breast tumorigenesis and confer …
rapamycin (mTOR)(PAM) pathways play important roles in breast tumorigenesis and confer …
AKT inhibitors: new weapons in the fight against breast cancer?
F Martorana, G Motta, G Pavone, L Motta… - Frontiers in …, 2021 - frontiersin.org
The serine/threonine kinase AKT is a key component of the PI3K/AKT/mTOR signaling
pathway as it exerts a pivotal role in cell growth, proliferation, survival, and metabolism …
pathway as it exerts a pivotal role in cell growth, proliferation, survival, and metabolism …
Targeting AKT for cancer therapy
M Shariati, F Meric-Bernstam - Expert opinion on investigational …, 2019 - Taylor & Francis
Introduction: Targeted therapies in cancer aim to inhibit specific molecular targets
responsible for enhanced tumor growth. AKT/PKB (protein kinase B) is a serine threonine …
responsible for enhanced tumor growth. AKT/PKB (protein kinase B) is a serine threonine …
ESR1 mutations in breast cancer
The acquisition of ligand‐independent ESR1 mutations during aromatase inhibitor therapy
in metastatic estrogen receptor (ER)‐positive breast cancer is a common mechanism of …
in metastatic estrogen receptor (ER)‐positive breast cancer is a common mechanism of …
Recent advances with precision medicine treatment for breast cancer including triple-negative sub-type
Simple Summary The progress of next-generation sequencing technologies has raised
huge expectations for precision-medicine therapy approaches in breast cancer and triple …
huge expectations for precision-medicine therapy approaches in breast cancer and triple …
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Abstract Background The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations
and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT …
and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT …
[HTML][HTML] Targeting autophagy-related protein kinases for potential therapeutic purpose
H **ang, J Zhang, C Lin, L Zhang, B Liu… - … Pharmaceutica Sinica B, 2020 - Elsevier
Autophagy, defined as a scavenging process of protein aggregates and damaged
organelles mediated by lysosomes, plays a significant role in the quality control of …
organelles mediated by lysosomes, plays a significant role in the quality control of …
Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer–A comprehensive review from chemotherapy to immunotherapy
Breast cancer is the most frequently occurring cancer in women. Chemotherapy in
combination with immunotherapy has been used to treat breast cancer. Atezolizumab …
combination with immunotherapy has been used to treat breast cancer. Atezolizumab …